Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7A592)

Drug Name

Bermekimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hidradenitis suppurativa	ED92.0	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-1 alpha (IL1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MABp1	DM8D13S	Colorectal cancer	2B91.Z	Phase 3	[3]
Xilonix	DMK34MZ	Colorectal cancer	2B91.Z	Phase 3	[4]
ABT-981	DM6PTIX	Osteoarthritis	FA00-FA05	Phase 2	[5]
Natrunix	DMBRSWJ	Arthritis	FA20	Phase 2	[6]
IX207-887	DM4TE8R	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[7]
IL1aQb	DMKS4Z9	Arteriosclerosis	BD40	Terminated	[8]
Interleukin-1-alpha - Amgen/Roche	DMB9AIX	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03512275) A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa. U.S.National Institutes of Health.
2	Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021 Jun;30 Suppl 1:8-17.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of xbiotech.
5	Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19.
6	ClinicalTrials.gov (NCT05363917) Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix Versus Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis. U.S.National Institutes of Health.
7	Inhibition of interleukin-1 release by IX 207-887. Agents Actions. 1990 Jun;30(3-4):350-62.
8	Cytos Biotechnology AG - Product Pipeline Review - 2013. Global Markets Direct. Dec 2013.
9	Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. 1993 Oct 15;268(29):22105-11.